Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C3H6FNO2
CAS Number:
Molecular Weight:
107.08
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12352100
EC Number:
223-318-3
MDL number:
Assay:
95%
Form:
solid
Product Name
3-Amino-2-fluoropropionic acid, 95%
InChI key
OJQNRNQELNLWHH-UHFFFAOYSA-N
InChI
1S/C3H6FNO2/c4-2(1-5)3(6)7/h2H,1,5H2,(H,6,7)
SMILES string
NCC(F)C(O)=O
assay
95%
form
solid
mp
240-245 °C
functional group
amine
carboxylic acid
fluoro
Quality Level
Related Categories
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Dam. 1 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Woo Young Kim et al.
Cancer science, 98(10), 1604-1608 (2007-08-09)
We studied whether total gastrectomy for gastric cancer would affect the pharmacokinetics of 5-fluorouracil (5-FU) and its degradation products, such as dihydrouracil (FUH(2)) and alpha-fluoro-beta-alanine (FBAL), after oral administration of the fluorouracil derivative S-1, composed of tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP; a
K Okuno et al.
Cancer chemotherapy and pharmacology, 42(4), 341-344 (1998-09-23)
The aim of this study was to identify the route of administration of 5-FU with the greatest pharmacological advantage in a rat model using non-invasive in vivo 19F nuclear magnetic resonance (NMR) spectroscopy. 5-FU (50 mg/kg) was administered to anesthetized
Bruno Reigner et al.
Cancer chemotherapy and pharmacology, 52(3), 193-201 (2003-06-05)
Capecitabine (Xeloda) is a novel, oral fluoropyrimidine carbamate rationally designed to generate 5-fluorouracil (5-FU) preferentially in tumor tissue via a three-step enzymatic cascade. The objective of this study was to compare the pharmacokinetics of capecitabine and its metabolites in Japanese
Jean-Louis Fischel et al.
Anti-cancer drugs, 15(10), 969-974 (2004-10-30)
Capecitabine (Xeloda) is a very active oral fluoropyrimidine (colon and breast cancers) whose clinical use is complicated by the presence of hand-foot syndrome (HFS). This cutaneous toxicity is less frequently encountered with other oral fluoropyrimidines containing a dihydropyrimidine dehydrogenase (DPD)
Ronald Gieschke et al.
British journal of clinical pharmacology, 55(3), 252-263 (2003-03-13)
To assess the relationship between systemic exposure to capecitabine metabolites and parameters of efficacy and safety in patients with advanced or metastatic colorectal cancer from two phase III studies. Concentration-effect analyses were based on data from 481 patients (248 males
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
